Significance of oral glucose tolerance tests in non-alcoholic fatty liver disease patients with a fasting plasma glucose level of <126 mg/dL and HbA1c level of ≤6.4% in Japan

Internal Medicine

Volumn 54, Issue 8, 2015, Pages 875-880

  Matsumoto, Naoki ^a   Arase, Yasuji ^a,b,c   Kawamura, Yusuke ^b   Ohmoto Sekine, Miki ^a   Amakawa, Kazuhisa ^a   Ogawa, Kyoko ^a   Tsuji, Hiroshi ^a   Dong, Hsieh Shiun ^a   Hara, Shigeko ^a   Akuta, Norio ^b   Suzuki, Fumitaka ^b   Suzuki, Yoshiyuki ^b   Ikeda, Kenji ^b   Kumada, Hiromitsu ^b   Kobayashi, Tetsurou ^c  

^a Okinaka Memorial Institute for Medical Research   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Non alcoholic fatty liver disease; Oral glucose tolerance test; Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ASSESSMENT; DIABETES MELLITUS; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FASTING PLASMA GLUCOSE LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HOMEOSTASIS MODEL FOR INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEFICIENCY; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; PATIENT ASSESSMENT; PREDICTION; RADIOIMMUNOASSAY; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; DIET RESTRICTION; EPIDEMIOLOGY; GLUCOSE TOLERANCE TEST; JAPAN; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PREDIABETIC STATE; PREVALENCE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; JAPAN; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDIABETIC STATE; PREVALENCE;

EID: 84927673808     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.54.3437     Document Type: Article

References (37)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
2. Williams R. Global changes in liver disease. Hepatology 44: 521 526, 2006.
3. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 134: 1682-1698, 2008.
4. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 49: 306-317, 2009.
5. Fan JC, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 50: 204-210, 2009.
6. Watanabe S, Yaginuma R, Ikejima K, et al. Liver diseases and metabolic syndrome. J Gastroenterol 43: 509-518, 2008.
7. Vega GL, Chandalia M, Szczepaniak LS, Grundy SM. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 46: 716-722, 2007.
8. van der Poorten D, Milner KL, Hui J, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 48: 449-457, 2008.
9. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 22: 1086-1091, 2007.
10. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30: 1356-1362, 1999.
11. Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 54: 333-339, 2005.
12. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 39: 909-914, 2004.
13. Tanné F, Gagnadoux F, Chazouillères O, et al. Chronic liver injury during obstructive sleep apnea. Hepatology 41: 1290-1296, 2005.
14. Arase Y, Suzuki F, Kobayashi M, et al. The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. Intern Med 50: 1081-1087, 2011.
15. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 294: E15-E26, 2008.
16. Arase Y, Suzuki F, Ikeda K, Kumada H, Tsuji H, Kobayashi T. Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastroenterol 44: 1064-1070, 2009.
17. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 13: 1579-1584, 2007.
18. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54: 3541-3546, 2005.
19. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45: 846-854, 2007.
20. Kawamura Y, Ikeda K, Arase Y, et al. Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J Gastroenterol Hepatol 23: 1739-1746, 2008.
21. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 46 (Suppl 1): 63-69, 2011.
22. Qiao Q, Nakagami T, Tuomilehto J, et al. Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia 43: 1470-1475, 2000.
23. Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome. Prevalence and determinants of a “bright” liver echopattern. Ital J Gastroenterol Hepatol 29: 351-356, 1997.
24. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 33 (Suppl 1): S11-S61, 2010.
25. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
26. The Committee of 370 Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Tonyobyo (J Jpn Diabetes Soc) 53: 450-467, 2010 (in Japanese).
27. Wong VW, Hui AY, Tsang SW, et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 24: 1215-1222, 2006.
28. Yun JW, Cho YK, Park JH, et al. Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. Liver Int 29: 525-529, 2009.
29. Heianza Y, Hara S, Arase Y, et al. HbA1c 5·7-6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet 378: 147-155, 2011.
30. Hatziagelaki E, Karageorgopoulos DE, Chounta A, Tsiavou A, Falagas ME, Dimitriadis G. Predictors of impaired glucose regulation in patients with non-alcoholic fatty liver disease. Exp Diabetes Res 2012: 351974, 2012.
31. Salgado AL, Carvalho Ld, Oliveira AC, Santos VN, Vieira JG, Parise ER. Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol 47: 165-169, 2010.
32. Sonsuz A, Basaranoglu M, Bilir M, Senturk H, Akin P. Hyperinsulinemia in nondiabetic, both obese and nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 97: 495, 2002.
33. Kimura Y, Hyogo H, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K. Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. J Gastroenterol Hepatol 26: 517-522, 2011.
34. Manchanayake J, Chitturi S, Nolan C, Farrell GC. Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 26: 510-516, 2011.
35. Hashiba M, Ono M, Hyogo H, et al. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PLoS One 8: e76161, 2013.
36. Nakahara T, Hyogo H, Yoneda M, et al; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol 49: 1477-1484, 2014.
37. Cheong JY, Um SH, Seo YS, et al. Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C. Dig Dis Sci 56: 555-563, 2011.